TG Therapeutics, Inc.

TG Therapeutics, Inc. Earnings Recaps

TGTX Health Care 3 recaps
Next earnings: February 25, 2027 (estimated) · full calendar
Q3 2026 Nov 10, 2026

TG Therapeutics raised 2026 global revenue guidance to $1 billion after reporting about $260 million in third-quarter revenue, including $233 million in U.S. BRIUMVI net revenue. The shares rose 5.9% after earnings.

Key takeaways
  • Management cited solid third-quarter performance and trends pointing to a strong fourth quarter as the basis for raising full-year revenue guidance.
  • About 35% of new anti-CD20 treatment starts are for self-administration, a segment BRIUMVI does not currently serve; the company expects Phase III results for subcutaneous BRIUMVI around year-end or early 2027 and is working toward a 2028 launch.
  • A Phase III study of a consolidated IV initiation dose was positive; TG is targeting potential approval around mid-2027.
  • The call highlighted early clinical results for azer-cel in progressive MS, while management also cited development programs in myasthenia gravis and treatment-resistant schizophrenia.
Q2 2026 Aug 5, 2026

Shares dropped 6.3% following the quarter as investors reacted negatively to a cautious outlook and the implied challenges expanding beyond the core BRIUMVI IV franchise, despite steady commercial execution and pipeline progress.

Key takeaways
  • BRIUMVI sales continued to grow, approaching a $1 billion annualized run rate with expanding physician adoption and new patient starts.
  • Positive Phase III ENHANCE data supported a simplified single-infusion initiation, potentially easing patient and provider burden by mid-2027.
  • Subcutaneous BRIUMVI showed promising Phase I bioavailability data; Phase III results are expected late this year or early next, with the subcutaneous formulation poised to roughly double the addressable market.
  • Early-stage expansion efforts include Phase I in myasthenia gravis and Phase II initiation in treatment-resistant schizophrenia, though these remain speculative and modest investments.
  • The cautious tone around broader franchise growth, timing uncertainties around subcutaneous data, and exploratory pipeline projects likely tempered enthusiasm, contributing to the stock’s material decline.
Q3 2025 Nov 5, 2025

TG Therapeutics reported robust Q3 2025 results, highlighted by impressive sales growth for BRIUMVI, which continues to outperform market expectations. The company remains committed to innovation and disciplined financial management.

Key takeaways
  • BRIUMVI generated approximately $153 million in U.S. net sales for Q3, exceeding internal targets and market forecasts.
  • Enrollment in pivotal studies for a simplified dosing schedule and subcutaneous ublituximab is progressing well, with potential launches anticipated in 2027 and 2028, respectively.
  • The recently completed $100 million share repurchase program and an additional authorized program reflect TG's commitment to returning capital to shareholders.
  • Continued strong demand and physician engagement for BRIUMVI highlight the growing preference for anti-CD20 therapies in MS treatment.
  • Intermediate data reveals significant efficacy and safety of BRIUMVI, with 90% of patients remaining free from disability progression after six years of treatment.